Skip to Content

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

This article reviews the outcomes of the CheckMate 914 trial, primarily focusing on Part B, which examined the efficacy of adjuvant Nivolumab (NIVO) monotherapy versus placebo (PBO) in patients with high-risk localized renal cell carcinoma (RCC) post-nephrectomy.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top